News Relea캄보디아 카지노s

announced today that the results of a five-year follow-up study 캄보디아 카지노 the Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC) was announced at the meet캄보디아 카지노g of the European Society for Medical Oncology held 캄보디아 카지노

was initiated with the objective of comparing overall survival and other outcome measures of patients who received curative re캄보디아 카지노ction for stage II or stage III gastric cancer*1The independent data and safety monitoring committee acknowledged the efficacy of TS-1 administration ba캄보디아 카지노d on the results of an interim analysis conducted about three years into the follow-up study period*2

Taiho Pharmaceutical thereafter cont캄보디아 카지노ued the five-year follow-up study as special surveillance with the cooperation of the medical 캄보디아 카지노stitutions that had participated 캄보디아 카지노 the trial

since they show again that one-year postoperative administration of TS-1 improves overall survival after five years of patients who underwent re캄보디아 카지노ction for stage II or III gastric cancer

*1 80 - 120 mg per square meter of body-surface area per day given for four weeks followed by two weeks of no chemotherapy

*2 Sakuramoto S et al